Glycoprotein News and Research

RSS

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

The influence of COVID-19 on platelet activation and aggregation

In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.

26 Aug 2021

SARS-CoV-2 alpha variant increased COVID-19 severity in Scotland's 3rd wave

A team of UK-based scientists has recently revealed that the alpha variant (B.1.1.7) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the third pandemic wave in Scotland and that the variant is associated with more severe coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.

25 Aug 2021

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant

A new study details the genomic characteristics and descent of a SARS-CoV-2 variant of interest.

23 Aug 2021

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

A new study describes how monoclonal antibodies raised against SARS-CoV-2 are affected by mutations in the antibody binding site.

20 Aug 2021

SARS-CoV-2 lambda variant escapes immune response via spike mutations

A new study explores the mechanism by which the SARS-CoV-2 lambda variant has acquired immune evasion capabilities above that of the wildtype.

20 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

Research suggests toll-like receptor 4 appears to play role in severe COVID

A group of researchers re-evaluated their previously proposed hypothesis, which stated that the TLR4 activated by the spike glycoprotein S1 domain increases ACE2 expression and, thereby, aids in COVID-19 infection.

16 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

A new study reports a more rapid method of viral inactivation in an effort to increase the appeal of inactivated viral vaccines against the COVID-19 pandemic.

10 Aug 2021

Natural vs. vaccine-induced COVID-19 immunity

A new paper discusses the protection offered by immunity against COVID-19 following vaccination as compared to natural infection.

10 Aug 2021

IMBA researchers may have found the "Achilles' heel" of SARS-CoV-2 virus

Researchers identify two sugar-binding proteins that impede the viral entry of circulating SARS-CoV-2 variants.

10 Aug 2021

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

The spike protein comprises of two subunits: S1 subunit having the receptor-binding domain (RBD) that helps it to bind to the angiotensin-converting enzyme 2 (ACE2), which is present on the cell surface of the host, and the S2 subunit that helps in the fusion of the cellular membrane and the viral membrane.

9 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Glycoprotein News and Research

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

The influence of COVID-19 on platelet activation and aggregation

SARS-CoV-2 alpha variant increased COVID-19 severity in Scotland's 3rd wave

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

SARS-CoV-2 lambda variant escapes immune response via spike mutations

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

How delta and kappa variants of SARS-CoV-2 evade the immune system

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

Research suggests toll-like receptor 4 appears to play role in severe COVID

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

Study shows efficacy of gamma irradiation of SARS-CoV-2 vaccine candidate in mouse model

Natural vs. vaccine-induced COVID-19 immunity

IMBA researchers may have found the "Achilles' heel" of SARS-CoV-2 virus

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

New insight into impact of SARS-CoV-2 mutations on receptor binding

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News